Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Comparative Effectiveness of Two Approaches to Diabetes Management in the Uninsured

16 juli 2015 bijgewerkt door: Edward Scott, Summa Health System

Comparative Effectiveness of Two Community Based Diabetes Management Approaches

The results of the pre-pilot and pilot studies will be used to determine the feasibility of a fully powered trial that will test the effectiveness of two different approaches to diabetes management in an uninsured diabetic population who receives their care from a community based free clinic, namely nurse-directed interdisciplinary care management compared to peer-led self management. Effective programs for the uninsured diabetic will benefit both the individual and society by preventing serious illness, decreasing mortality and disability, decreasing medical debt, stimulating economic growth, improving business productivity, reducing job lock, decreasing health disparities, improving quality of life, and reducing cost shifting by decreasing uncompensated care. Findings will be generalizable to uninsured and insured patients across a wide spectrum of chronic conditions.

Studie Overzicht

Toestand

Voltooid

Conditie

Gedetailleerde beschrijving

The randomized pre-pilot and pilot studies will inform the design of a fully powered trial that will test the effectiveness of a nurse-led interdisciplinary care management intervention (CM) for improving hemoglobin A1c in uninsured diabetic patients who receive their primary medical care from a community-based free clinic compared to similar patients who undergo peer-led self management (SM). The comparative effectiveness of these approaches has not been tested in a randomized trial.

To ensure the success of the pilot study the investigators will perform a 6 month pre-pilot study using 10 patients per group. This pre-pilot will be used to establish protocols covering enrollment, HIPAA, consent, interventions and outcome measurement. The subsequent 1 year pilot will be used to demonstrate feasibility, estimate recruitment, attendance and follow up, refine inclusion criteria, provide power analysis, optimize the interventions and determine appropriate secondary outcomes for a fully powered trial. For the pilot, thirty patients will be randomized to the CM intervention for the first 6 months. Major components of the nurse-led CM model include: 1) assessment and goal setting for self-management; 2) education for self efficacy and productive clinical encounters; 3) access to specialist care via an interdisciplinary team; 4) evidence-based treatment recommendations responsive to patients' goals; and 5) care coordination by a nurse care manager. From 6-12 months patients will return to usual clinic care.

The 30 patients randomized to the SM group will be invited to attend weekly peer-led SM training broadly based on the Stanford University Diabetes Self-management Program's Train the Trainer Model. The training will occur over 6 weeks and will cover topics common to most chronic disease SM programs including: goal setting, self-management of chronic conditions, making action plans, feedback and problem solving, handling emotions, symptom management techniques, communication with health care providers, medications and making treatment decisions. The peer advisors and a nurse will then lead 1 hour monthly group sessions for the remainder of the first 6 months for review/revision of action plans, review of self management techniques and ongoing social persuasion and modeling. From 6-12 months patients will return to usual clinic care.

For the pilot, outcome measures will be obtained at 6 and 12 months. For this pilot, the investigators will not test any hypotheses. Instead, effect sizes and confidence intervals will be calculated for each outcome. These results will be used for power analysis. The results will also allow us to see which interventions are most effective on which outcomes and allow us to optimize the interventions to have the greatest impact on the primary outcome, hemoglobin A1c. Cost effectiveness will be determined in a fully powered trial.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

64

Fase

  • Niet toepasbaar

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

25 jaar tot 75 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • patients will be eligible if they are between the ages of 25 and 75,
  • have a diagnosis of diabetes (type II) with a hemoglobin A1c >[7.0] There will be no exclusions based on gender, race or ethnicity.

Exclusion Criteria:

  • have no other illness that would dominate their care (e.g., terminal cancer, numerous exacerbations of CHF), and
  • are not pregnant.
  • patients must have no cognitive impairment.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Onderzoek naar gezondheidsdiensten
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Nurse-led care management
Nurse-led care management involves a nurse care manager who performs a comprehensive assessment of the patient then presents those assessment findings to an interdisciplinary team. The team makes care recommendations that are implemented by the care manager in collaboration with the patient's PCP.
Experimenteel: peer-led self managment
Peer-led self management follows the chronic disease self management model where peer counselors lead self management classes for 6 weeks, then conduct monthly support groups

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
hemoglobin A1c
Tijdsspanne: change from baseline at 6 months for pre-pilot and change from baseline at 6 months and change from baseline at 12 months for pilot
change from baseline at 6 months for pre-pilot and change from baseline at 6 months and change from baseline at 12 months for pilot

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Edward D Scott, MD, Summa Health System

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 augustus 2011

Primaire voltooiing (Werkelijk)

1 april 2015

Studie voltooiing (Werkelijk)

1 april 2015

Studieregistratiedata

Eerst ingediend

20 juli 2012

Eerst ingediend dat voldeed aan de QC-criteria

27 juli 2012

Eerst geplaatst (Schatting)

31 juli 2012

Updates van studierecords

Laatste update geplaatst (Schatting)

20 juli 2015

Laatste update ingediend die voldeed aan QC-criteria

16 juli 2015

Laatst geverifieerd

1 juli 2015

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • shs250014
  • 1R03DK090351-01 (Subsidie/contract van de Amerikaanse NIH)

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren